Research Papers:

Genomic characterization of metastatic ultra-hypermutated interdigitating dendritic cell sarcoma through rapid research autopsy

Hui-Zi Chen, Russell Bonneville, Lianbo Yu, Michele R. Wing, Julie W. Reeser, Melanie A. Krook, Jharna Miya, Eric Samorodnitsky, Amy Smith, Dorrelyn Martin, Thuy Dao, Qishan Guo, David Liebner, Aharon G. Freud, Patricia Allenby and Sameek Roychowdhury _

PDF  |  Full Text  |  Supplementary Files  |  How to cite  |  Press Release  |  Podcast  |  Video Interview

Oncotarget. 2019; 10:277-288. https://doi.org/10.18632/oncotarget.26352

Metrics: PDF 1979 views  |   Full Text 3920 views  |   ?  


Hui-Zi Chen1,2,*, Russell Bonneville1,3,*, Lianbo Yu4, Michele R. Wing1, Julie W. Reeser1, Melanie A. Krook1, Jharna Miya1, Eric Samorodnitsky1, Amy Smith1, Dorrelyn Martin1, Thuy Dao1, Qishan Guo1, David Liebner1,4, Aharon G. Freud5, Patricia Allenby6 and Sameek Roychowdhury1

1Department of Internal Medicine, Division of Medical Oncology, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, USA

2Department of Internal Medicine, Hematology and Oncology Fellowship Program, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, USA

3Biomedical Sciences Graduate Program, The Ohio State University, Columbus, Ohio, USA

4Department of Biomedical Informatics, The Ohio State University, Columbus, Ohio, USA

5Department of Pathology, Division of Hematopathology, The Ohio State University, Columbus, Ohio, USA

6Department of Pathology, Division of Autopsy Services, The Ohio State University, Columbus, Ohio, USA

*These authors contributed equally to this work

Correspondence to:

Sameek Roychowdhury, email: [email protected]

Keywords: tumor heterogeneity; research autopsy; hypermutation

Received: October 24, 2018     Accepted: October 31, 2018     Published: January 08, 2019


Interdigitating dendritic cell sarcoma (IDCS) is an extremely rare cancer of dendritic cell origin that lacks a standardized treatment approach. Here, we performed genomic characterization of metastatic IDCS through whole exome sequencing (WES) of tumor tissues procured from a patient who underwent research autopsy. WES was also performed on a treatment-naïve tumor biopsy sample obtained from prior surgical resection. Our analyses revealed ultra-hypermutation, defined as >100 mutations per megabase, in this patient's cancer, which was further characterized by the presence of three distinct mutational signatures including UV radiation and APOBEC signatures. To characterize clonal heterogeneity, we used the bioinformatics tool Canopy to leverage single nucleotide and copy number variants to catalog six subclones across various metastatic tumors. Truncal alterations, defined as being present in all clonal tumor cell populations, in this patient's cancer include point mutations in TP53 and CDKN2A and amplifications of c-KIT and APOBEC3A-H, which are likely driver mutations. In summary, we have performed genomic characterization evaluating tumor mutational burden (TMB) and heterogeneity in a patient with metastatic IDCS. Despite ultra-hypermutation, this patient's cancer was not responsive to treatment with PD-1 inhibition. Our results underscore the importance of characterizing clonal heterogeneity in TMB-high cancers.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 26352